This guideline extends the earlier BSPGHAN guideline (based on NASPGHAN Celiac Guideline of 2005 1 and the original guideline from the Welsh Paediatric Gastroenterology MCN 2 ) to incorporate the changed ESPGHAN 2012 diagnostic guideline 3 . The BSG Coeliac Guideline for Adult Coeliac Disease is available on the BSG website www.bsg.org.uk Coeliac Disease (CD) is an immune-mediated systemic disorder, strongly dependent on the HLA-DQ2 and DQ8 haplotypes. It is elicited by gluten and related prolamines in genetically susceptible individuals, and characterised by a variable combination of gluten dependent clinical manifestations, CD specific antibodies and enteropathy [3] [4] [5] [6] [7] .
Who to test
The prevalence of coeliac disease is estimated to be 1:100 in the UK. Universal population screening is not currently advised. However there should be a low threshold for investigating both symptomatic children and those with associated conditions, as it is recognised that approximately 90% of cases remain undiagnosed. 
Blood antibody testing to screen for coeliac disease
Initial screening requires estimation of total IgA and IgA anti-tTG antibodies. Findings of positive anti-tTG antibody or IgA deficiency require further diagnostic action -usually a small bowel biopsy or (only in certain specific circumstances detailed below) a second blood test for EMA testing and HLA-DQ typing 3 .
In the case of IgA deficiency: IgG tTG or IgG EMA may help to decide on need for biopsy. However neither IgG tTG nor IgG EMA are as specific as IgA antibodies. Biopsy may still be clinically indicated if these tests are negative. Also consider: JCA, epilepsy, with associated intracranial calcification, unexplained neurological problems (palsies, neuropathies, migraine).
For symptomatic cases
If screening parents / patients, families should be advised pre-testing about relative risks of untreated coeliac disease and need for biopsy and gluten-free diet should blood tests come back positive.
Ensure adequate gluten intake pre-testing and consult dietitian if formal assessment required (see Section 3 and Appendix 1)
If possible, test when venesection done for other reasons (annual review etc).
• Recurrent aphthous stomatitis • Unexplained liver disease • Lassitude / weakness.
Also consider: JCA, epilepsy, with associated intracranial calcification, unexplained neurological problems (palsies, neuropathies, migraine).
If screening parents / patients, families should be advised pre-testing about relative risks of untreated coeliac disease and need for biopsy and GFD should blood tests come back positive.
Ensure adequate gluten intake pre-testing and consult dietitian if formal assessment required (see section 3 and Appendix 1)
Confirmation of the diagnosis
Anti-tTG antibody positivity alone is insufficient for diagnosis.
Therapeutic trials of gluten-free diet (GFD) are NOT indicated if coeliac disease is suspected.
Children should not be started on a GFD on the basis of an antibody test alone, unless their clinical condition is so poor that treatment cannot safely be delayed (eg coeliac crisis). It is recommended that such cases should be discussed with a paediatric gastroenterologist. 
Confirmation

c)
If tTG raised -and greater than 10 x upper limit of normal for assay Take further blood sample to check IgA EMA and determine HLA-DQ2/ DQ8 typing. If EMA+ and patient either DQ2 or DQ8, the diagnosis is confirmed without the need for a duodenal biopsy. If EMA antibody testing is not locally available, a second strongly positive tTG antibody may be substituted and serum saved for later EMA testing.
OR
Perform duodenal biopsy as above.
deficiency, positive family history) perform endoscopy and duodenal biopsies including biopsies of the duodenal cap (which may sometimes show diagnostic abnormalities where the more distal duodenum appears normal) to identify seronegative coeliac disease and other mucosal disorders.
For asymptomatic cases
In asymptomatic children with associated condition and negative serology, consider HLA typing
• If HLA DQ2 / DQ8 positive: continue surveillance (optimum frequency for repeat blood testing unclear but every 3 years is reasonable if asymptomatic) and perform endoscopy if symptomatic.
• If HLA DQ2/DQ8 negative: development of CD highly unlikely 9 . Discontinue regular antibody screening but clinical review if suggestive symptoms develop.
Explain implication of positive test and obtain and document consent for testing. ALL such children will require small intestinal biopsy for diagnosis to be confirmed. 
Interpretation of small bowel histology
The modified Marsh grading system is now accepted as the standard method of analysis 10 .
Villous atrophy with crypt hyperplasia and increased intraepithelial lymphocytes (IELs) >30/100 epithelial cells (Marsh type 3) characteristic of coeliac disease.
Increased IELs with crypt hyperplasia (Marsh type 2) compatible with coeliac disease
• diagnosis strengthened by positive serology • if serology negative, reconsider coeliac disease after exclusion of other disorders.
Increased IELs with normal villous architecture (Marsh type 1) is non-specific for coeliac disease but
• diagnosis strengthened by strongly positive serology.
If diagnosis uncertain with negative serology and mild infiltrative changes, the options are:
• Perform HLA typing (DQ2 and DQ8) if not already checked • Consider repeat biopsy after further challenge with increased gluten intake (if very strong clinical suspicion but histology negative or non-classical, enteroscopy may be considered) • Consider repeat serology and biopsy after trial of GFD • Document basis for diagnosis in case notes (Appendix 2) • Document response to GFD in case notes at follow up.
Non-coeliac gluten sensitivity occurs in persons with a reproducibly adverse response to ingesting gluten, either symptomatic or on small intestinal biopsy, in whom coeliac disease has been excluded. Potential causes include Non-IgE-mediated food allergy.
Who to treat with gluten-free diet A. All symptomatic children with characteristic abnormal histology Benefits of gluten-free diet
Resolution of symptoms Reversed bone demineralisation (if pre-pubertal) Resolution of micronutrient deficiencies Decreased rate of delayed puberty, menstrual problems, sub-fertility, spontaneous abortions and LBW babies Decreased rate of some intestinal cancers to normal population levels Possible prevention of onset of other autoimmune conditions (evidence conflicting).
B. Asymptomatic children with a condition associated with CD and characteristic histology Benefits of gluten-free diet
Likely to reverse covert micronutrient deficiency and optimise bone mineralization Unclear whether diabetes control improves No studies on long term outcomes of GFD in children with associated conditions.
Terms such as silent coeliac disease, latent coeliac disease and overt coeliac disease are no longer recommended.
How to treat
Start GFD after diagnosis confirmed by histology. GFD will be a lifelong requirement and needs regular paediatric dietetic support, ideally initiated within 1-2 weeks of diagnosis. It should be followed up at 3-6 monthly intervals in the first year and thereafter annually. Additional input may be required if there are problems with dietary adherence.
Sensitivity to gluten, and acknowledgment of symptoms after ingestion is variable between patients. Small amounts of gluten ingested regularly can cause mucosal changes even if patient feels asymptomatic.
From 2012, only foods that contain 20ppm or less can be labelled as 'gluten-free'.
This may apply both to specialist substitute gluten-free products and processed foods which are naturally gluten-free products like soups, baked beans and crisps. The 'gluten-free' label may also be used for uncontaminated oat products. Specialist substitute foods (eg breads and pasta containing Codex wheat starch) containing between 21 and 100ppm gluten may be labelled as 'very low gluten'.
These guidelines are more stringent than previous UK definitions of "gluten-free" and are covered by law.
• Oats are safe for most patients with coeliac disease -although around 5% of patients will be sensitive to oats. It is essential that patients use only uncontaminated oats. These will be labelled gluten-free.
• Ideally establish patient on strict GFD excluding oats and consider reintroduction when baseline of wellness achieved, often after at least one year on GFD. Monitor carefully for signs or symptoms.
• Normalisation of tTG prior to commencing oats, and continued low titres after reintroduction may provide further reassurance.
How to monitor
The majority of patients/parents are well motivated and access good levels of support from Coeliac UK. Ongoing monitoring by an experienced paediatric dietitian and paediatric gastroenterologist or paediatrician with a special interest is still necessary to ensure long-term adherence.
• Post diagnosis clinical assessment by a clinician and dietitian experienced in the care of children and young people with CD (symptoms, growth, physical examination, micronutrient status, adherence to GFD), dietary intake of calcium and iron and anti-tTG antibodies 6 to 12 months after starting GFD 
Gluten challenge to confirm diagnosis when initial diagnosis uncertain
Routine re-challenge is not required if diagnosis is secure. If initial diagnosis is insecure and the child is on a gluten-free diet, then further testing is recommended.
HLA testing is a useful initial screen in these circumstances. If HLA-DQ2 and DQ8 negative, then the child is unlikely to have true coeliac disease. If HLA-DQ2 or DQ8 positive, then a formal gluten challenge will be required for clarification of the diagnosis.
Three months gluten challenge prior to testing is advised if asymptomatic with option to
• Most coeliac patients tolerate Codex wheat starch and gluten-free barley malt extract. Products containing barley malt extract must be below 20ppm to be labelled gluten-free. Codex wheat starch can be used in both products labelled gluten-free, <20 or very low gluten 21-100. The <20 level is safe for all unless they have a separate non-coeliac sensitivity to the wheat. The 21 -100 levels should be acceptable for most coeliac patients, but not those with high sensitivity to gluten.
• Codex wheat starch is used in some gluten-free products available on prescription, so the suitability should be established prior to prescribing.
• Lactose-free diet is very rarely needed, although in some, temporary lactose intolerance can co-exist and may need specific dietetic advice. More persistent lactose intolerance suggests the need for further assessment to exclude inadequate dietary compliance or additional pathology requiring separate treatment (eg cow's milk sensitive enteropathy).
• Ensure easy access to paediatric dietitian(s).
Advise families to join Coeliac UK, whose website is www.coeliac.org.uk.
Coeliac UK, Third Floor, Apollo Centre, Desborough Road, High Wycombe, Bucks HP11 2QW. Helpline: 0845 305 2060.
Amongst various forms of support to families, the Food and Drink Directory and monthly updates/ deletions remains the easiest way to obtain information about a wide range of suitable gluten-free manufactured foods.
Pneumococcal vacine
This is now recommended for patients with coeliac disease (Coeliac UK guidelines). Many children will already have had this as part of their routine immunisation programme.
expedite blood testing when patient develops symptoms. A minimum duration of 4-6 weeks for those with symptoms during gluten challenge is recommended to maximise the likelihood of clear diagnosis. Biopsy should be performed when serology becomes positive or symptoms are difficult to tolerate.
If considering gluten challenge:
• Perform at age 6 -7 years or when pubertal growth complete • This is best managed by increasing gluten within the normal diet (see Appendix 1 for recommended intake). Gluten powder (10-15 g/day) is an alternative, but is less palatable and difficult to obtain.
• Monitor symptoms and serum anti-tTG antibodies, repeating biopsy if serology becomes positive. Patients require follow up for at least 2 years post challenge with serology at 6 monthly intervals if remaining symptom free. Consider biopsy at 2 years even if asymptomatic. Patients should be advised that much later relapse may occur 11 , and thus they should be referred again for gastro enterological assessment if they ever develop symptoms suggestive of coeliac disease.
